| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |